KR102240357B1 - Antioxidant composition for cosmetics containing a compound isolated from extract of Rosa rugosa Thumb - Google Patents
Antioxidant composition for cosmetics containing a compound isolated from extract of Rosa rugosa Thumb Download PDFInfo
- Publication number
- KR102240357B1 KR102240357B1 KR1020180172779A KR20180172779A KR102240357B1 KR 102240357 B1 KR102240357 B1 KR 102240357B1 KR 1020180172779 A KR1020180172779 A KR 1020180172779A KR 20180172779 A KR20180172779 A KR 20180172779A KR 102240357 B1 KR102240357 B1 KR 102240357B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- compound
- formula
- isolated
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 58
- 239000000284 extract Substances 0.000 title claims abstract description 50
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 22
- 239000000203 mixture Substances 0.000 title claims abstract description 21
- 239000003963 antioxidant agent Substances 0.000 title claims abstract description 13
- 239000002537 cosmetic Substances 0.000 title claims abstract description 13
- 235000000659 Rosa rugosa Nutrition 0.000 title 1
- 240000006066 Rosa rugosa Species 0.000 title 1
- 210000003813 thumb Anatomy 0.000 title 1
- 239000002038 ethyl acetate fraction Substances 0.000 claims abstract description 14
- 239000004480 active ingredient Substances 0.000 claims abstract description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 238000004440 column chromatography Methods 0.000 claims description 6
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 6
- 238000000746 purification Methods 0.000 claims 1
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 12
- 239000002904 solvent Substances 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 238000010586 diagram Methods 0.000 description 8
- 235000006708 antioxidants Nutrition 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 4
- 229940125904 compound 1 Drugs 0.000 description 4
- 239000002032 methanolic fraction Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 229940126214 compound 3 Drugs 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- 229940093499 ethyl acetate Drugs 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 240000000724 Berberis vulgaris Species 0.000 description 2
- 235000016068 Berberis vulgaris Nutrition 0.000 description 2
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 230000002292 Radical scavenging effect Effects 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 2
- 238000013375 chromatographic separation Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- -1 flavonoid compounds Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 238000002114 high-resolution electrospray ionisation mass spectrometry Methods 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000001946 ultra-performance liquid chromatography-mass spectrometry Methods 0.000 description 2
- 238000002211 ultraviolet spectrum Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- 229930013915 (+)-catechin Natural products 0.000 description 1
- 235000007219 (+)-catechin Nutrition 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- CUOZRGBQTOSWAY-UHFFFAOYSA-N Arjunetin Natural products C1CC(C2(CCC3C(C)(C)C(O)C(O)CC3(C)C2CC=2)C)(C)C=2C2C(O)C(C)(C)CCC21C(=O)OC1OC(CO)C(O)C(O)C1O CUOZRGBQTOSWAY-UHFFFAOYSA-N 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 229930182603 Euscaphic acid Natural products 0.000 description 1
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 1
- OVSQVDMCBVZWGM-IDRAQACASA-N Hirsutrin Natural products O([C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1)C1=C(c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1=O OVSQVDMCBVZWGM-IDRAQACASA-N 0.000 description 1
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- 206010056344 Menstrual discomfort Diseases 0.000 description 1
- PZZRDJXEMZMZFD-ODPGBAFUSA-N Reynoutrin Natural products O[C@H]1[C@H](O)[C@@H](O)CO[C@@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O PZZRDJXEMZMZFD-ODPGBAFUSA-N 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- FMQQLXJREAGPHS-UHFFFAOYSA-N Tellimoside Natural products O1C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)C(O)C(O)C(O)C1COC(=O)C1=CC(O)=C(O)C(O)=C1 FMQQLXJREAGPHS-UHFFFAOYSA-N 0.000 description 1
- FMQQLXJREAGPHS-OJWSHTDTSA-N [(2r,3r,4s,5r,6s)-6-[2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxochromen-3-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl 3,4,5-trihydroxybenzoate Chemical compound C([C@@H]1[C@@H]([C@@H]([C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1)O)O)OC(=O)C1=CC(O)=C(O)C(O)=C1 FMQQLXJREAGPHS-OJWSHTDTSA-N 0.000 description 1
- MLKQAGPAYHTNQQ-BRDPIYJESA-N [(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (1r,2r,4as,6ar,6as,6br,8ar,10r,11r,12ar,14bs)-1,10,11-trihydroxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate Chemical compound O=C([C@]12CC[C@H]([C@@]([C@H]1C=1[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)(C)O)C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O MLKQAGPAYHTNQQ-BRDPIYJESA-N 0.000 description 1
- CUOZRGBQTOSWAY-PWEPJYDOSA-N [(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (1s,4ar,6ar,6as,6br,8ar,10r,11r,12ar,14bs)-1,10,11-trihydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate Chemical compound O=C([C@]12CCC([C@H]([C@H]1C=1[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)O)(C)C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CUOZRGBQTOSWAY-PWEPJYDOSA-N 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- BDCDNTVZSILEOY-UXYNSRGZSA-N avicularin Chemical compound O[C@@H]1[C@@H](O)[C@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O BDCDNTVZSILEOY-UXYNSRGZSA-N 0.000 description 1
- QIARVOTYSDZZQL-UHFFFAOYSA-N avicularin Natural products OCC1OC(Oc2cc(O)c3C(=O)C(=C(Oc3c2)c4ccc(O)c(O)c4)O)C(O)C1O QIARVOTYSDZZQL-UHFFFAOYSA-N 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 1
- 235000000431 campesterol Nutrition 0.000 description 1
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- OXVUXGFZHDKYLS-QUFHAEKXSA-N euscaphic acid Chemical compound C1[C@@H](O)[C@@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@](O)(C)[C@H]5C4=CC[C@@H]3[C@]21C OXVUXGFZHDKYLS-QUFHAEKXSA-N 0.000 description 1
- 238000002270 exclusion chromatography Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- ALRFYJWUVHBXLV-UHFFFAOYSA-N guaijaverin Natural products OC1COC(COC2=C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(O)c4)C(O)C1O ALRFYJWUVHBXLV-UHFFFAOYSA-N 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- NQYPTLKGQJDGTI-FCVRJVSHSA-N hyperoside Natural products OC[C@H]1O[C@@H](OC2=C(Oc3cc(O)cc(O)c3[C@H]2O)c4ccc(O)c(O)c4)[C@H](O)[C@@H](O)[C@H]1O NQYPTLKGQJDGTI-FCVRJVSHSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- GXMWXESSGGEWEM-UHFFFAOYSA-N isoquercitrin Natural products OCC(O)C1OC(OC2C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(O)c4)C(O)C1O GXMWXESSGGEWEM-UHFFFAOYSA-N 0.000 description 1
- 229940087875 leukine Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- BDCDNTVZSILEOY-UHFFFAOYSA-N polystachoside Natural products OC1C(O)C(CO)OC1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O BDCDNTVZSILEOY-UHFFFAOYSA-N 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 description 1
- OVSQVDMCBVZWGM-QSOFNFLRSA-N quercetin 3-O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-QSOFNFLRSA-N 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 description 1
- QGTBWTXRSOKBBE-QZIYNGKJSA-N rosamultin Natural products CC1(C)[C@@H](O)[C@H](O)C[C@@]2(C)[C@H]1CC[C@]3(C)[C@@H]2CC=C4[C@@H]5[C@@](C)(O)C(C)(C)CC[C@@]5(CC[C@@]34C)C(=O)O[C@@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O QGTBWTXRSOKBBE-QZIYNGKJSA-N 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 108010038379 sargramostim Proteins 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- MLKQAGPAYHTNQQ-UHFFFAOYSA-N tormentic acid glucosyl ester Natural products C1CC(C2(CCC3C(C)(C)C(O)C(O)CC3(C)C2CC=2)C)(C)C=2C2C(O)(C)C(C)CCC21C(=O)OC1OC(CO)C(O)C(O)C1O MLKQAGPAYHTNQQ-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Birds (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Alternative & Traditional Medicine (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medical Informatics (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
본 발명은 매괴화 추출물로부터 분리한 화학식 1 내지 6의 화합물로 이루어진 군으로부터 선택되는 1 종 이상의 화합물을 유효성분으로 함유하는 것을 특징으로 하는 화장품용 항산화 조성물에 관한 것이다.
상기 매괴화 추출물로부터 분리한 화합물을 유효성분으로 함유하는 화장품용 항산화 조성물은 매괴화 추출물의 에틸아세테이트 분획물로부터 효율적으로 화합물 1 내지 6을 분리하여 항산화 성분을 갖는 화장품의 조성물로 유용하게 사용될 수 있는 효과가 있다.
The present invention relates to an antioxidant composition for cosmetics, characterized in that it contains as an active ingredient at least one compound selected from the group consisting of compounds of Formulas 1 to 6 isolated from the maemaehwa extract.
Antioxidant composition for cosmetics containing the compound isolated from the maemaebu extract as an active ingredient effectively separates the compounds 1 to 6 from the ethyl acetate fraction of the maebubu extract and can be usefully used as a cosmetic composition having an antioxidant component. There is.
Description
본 발명은 매괴화 추출물로부터 분리한 화합물을 유효성분으로 함유하는 화장품용 항산화 조성물에 관한 것으로, 더 상세하게는 매괴화를 용매로 추출한 후 분획용매로써 물과 에틸아세테이트를 각각 사용하여 분획한 분획추출물을 분리한 화합물을 유효성분으로 함유한 항산화 효과가 우수한 조성물에 관한 것이다. The present invention relates to a cosmetic antioxidant composition containing as an active ingredient a compound isolated from a maebu extract, and more particularly, a fractionated extract obtained by extracting maebu with a solvent and then using water and ethyl acetate as fractionation solvents, respectively. It relates to a composition having an excellent antioxidant effect containing a compound separated by as an active ingredient.
매괴화는 장미과에 속한 해당화의 꽃봉오리를 말한다. 해당화는 주로 바닷가 모래땅이나 산기슭에 자생하는 낙엽활엽관목으로, 잎은 어긋나며 작은 잎은 타원형 또는 도란형으로 밑이 날카롭고 끝은 뭉뚝하거나 또는 둥글며 톱니가 있고 뒷면에 선점과 융모가 있다. 꽃은 붉은색으로 5월에 피고, 과실은 가장과로 거의 구형이며 황적색으로 8월에 익는다. 해당화의 화학적 성분으로 β-sitosterol, campesterol, euscaphic acid, β-sitosteryl-β-D-glucopyanoside, campesteryl-β-D-glucopyranoside, rosamultin, arjunetin, (+)-catechin 등이 알려져있다. Plum blossom refers to the flower buds of the flower belonging to the Rosaceae family. This flower is a deciduous broad-leaved shrub that grows naturally in the sandy area of the beach or at the foot of the mountain. The leaves are dislocated, the small leaves are oval or obovate, the bottom is sharp, the ends are blunt or round, serrated, and there are preoccupants and villi on the back side. The flower is red and blooms in May, and the fruit is the most globular, yellow-red, and ripens in August. Chemical components of glycosylation include β-sitosterol, campesterol, euscaphic acid, β-sitosteryl-β-D-glucopyanoside, campesteryl-β-D-glucopyranoside, rosamultin, arjunetin, and (+)-catechin.
매괴화는 비(脾), 간(肝)의 이경(二經)에 들어가서 혈(血)을 통하게 하고, 기(氣)를 이롭게 하며, 풍비(風)를 치료하는 약물이다. 행혈(行血), 조경(調經), 항염증약으로서 위통(胃痛), 유옹종통(乳癰腫痛), 월경불조(月 經不調), 류마티스, 타박상(打撲傷) 등에 사용한다.Maedanghwa is a drug that enters the nose of the nose and liver, allows blood to pass through, benefits Gi, and cures wind. As an anti-inflammatory drug, it is used for blood circulation, landscaping, stomach pain, Yuongjongtong, menstrual discomfort, rheumatism, and bruises.
근래에는 매괴화 추출물 및 분획물의 항산화 활성을 인정받았지만, 특정 화합물의 항산화 활성에 대해서는 보고된 바가 없다. In recent years, the antioxidant activity of the extracts and fractions of barberry has been recognized, but there has been no report on the antioxidant activity of specific compounds.
본 발명은 상기 종래기술이 갖는 문제점을 해결하기 위해서 안출된 것으로서, 본 발명에서 해결하고자 하는 과제는 매괴화 추출물로부터 분리된 화합물을 유효성분으로 함유하는 화장품용 항산화 조성물을 제공하는데 그 목적이 있다.The present invention has been conceived to solve the problems of the prior art, and an object to be solved in the present invention is to provide an antioxidant composition for cosmetics containing a compound isolated from a maebustion extract as an active ingredient.
또한, 매괴화 추출물로부터 화학식 1 내지 6으로 표시되는 화합물을 분리하는 제조방법을 제공하는데 그 목적이 있다.In addition, it is an object of the present invention to provide a method for separating the compounds represented by Chemical Formulas 1 to 6 from the extract of maebustion.
상기와 같은 목적을 달성하기 위한 본 발명에 따른 매괴화 추출물로부터 분리한 화합물을 유효성분으로 함유하는 화장품용 항산화 조성물은 매괴화 추출물로부터 분리한 화학식 1 내지 6의 화합물로 이루어진 군으로부터 선택되는 1 종 이상의 화합물을 유효성분으로 함유하는 것을 특징으로 한다.Cosmetic antioxidant composition containing as an active ingredient the compound isolated from the maebustion extract according to the present invention for achieving the above object is one selected from the group consisting of the compounds of
또, 상기 매괴화 추출물의 추출용매는 물, 알코올 또는 이들의 혼합물인 것을 특징으로 한다. In addition, the extraction solvent of the plume extract is characterized in that water, alcohol, or a mixture thereof.
또, 상기 매괴화 추출물로부터 분리한 화학식 1 내지 6의 화합물은 매괴화 추출물의 에틸아세테이트 분획물로부터 분리된 것을 특징으로 한다.In addition, the compounds of
또, 상기 매괴화 추출물로부터 분리한 화학식 1 내지 6의 화합물은 컬럼 크로마토그래피, 고성능액체 크로마토그래피, 이온교환 크로마토그래피, 친화성 크로마토그래피 및 크기배제 크로마토그래피로 이루어진 군으로부터 선택되는 1 종 이상을 사용하여 분리하는 것을 특징으로 한다.In addition, the compounds of
또, 상기 매괴화 추출물의 에틸아세테이트 분획물로터 분리된 화합물을 0.1~10중량%를 유효성분으로 포함하는 것을 특징으로 한다.In addition, it is characterized in that it comprises 0.1 to 10% by weight of the separated compound as an active ingredient from the ethyl acetate fraction of the lumped extract.
본 발명에 따른 매괴화 추출물로부터 분리한 화합물을 유효성분으로 함유하는 화장품용 항산화 조성물은 매괴화 추출물의 에틸아세테이트 분획물로부터 효율적으로 화합물 1 내지 6을 분리하여 항산화 성분을 갖는 화장품의 조성물로 유용하게 사용될 수 있는 효과가 있다.Cosmetic antioxidant composition containing as an active ingredient the compound isolated from the maebustion extract according to the present invention is effectively used as a cosmetic composition having an antioxidant component by separating
도 1은 본 발명에 따른 매괴화로부터 분리한 화합물 1 내지 6의 분리과정을 나타낸 도면이다.
도 2는 본 발명에 따른 매괴화 추출물의 에틸아세테이트 분획물의 DPPH 활성을 나타낸 도면이다.
도 3은 본 발명에 따른 50% 메탄올 분획물의 DPPH 활성을 나타낸 도면이다.
도 4는 본 발명에 따른 50% 메탄올 분획물에서 분리된 6개의 화합물에 대한 DPPH 활성을 나타낸 것이다.
도 5는 본 발명에 따른 매괴화 추출물에서 분리된 6개의 화합물의 UPLC를 분석한 결과를 나타낸 도면이다.
도 6은 본 발명에 따른 매괴화 추출물에서 분리된 6개의 화합물의 자외선 스펙트럼을 나타낸 도면이다.
도 7은 본 발명에 따른 매괴화 추출물에서 분리된 6개의 화합물의 UPLC-HR-ESI-MS 스펙트럼을 나타낸 도면이다.
도 8은 본 발명에 따른 매괴화 추출물에서 분리된 6개의 화합물 중 화합물 1의 1H NMR 스펙트럼을 나타낸 도면이다.
도 8은 본 발명에 따른 매괴화 추출물에서 분리된 6개의 화합물 중 화합물 1의 1H NMR 스펙트럼을 나타낸 도면이다.
도 9는 본 발명에 따른 매괴화 추출물에서 분리된 6개의 화합물 중 화합물 2의 1H NMR 스펙트럼을 나타낸 도면이다.
도 10은 본 발명에 따른 매괴화 추출물에서 분리된 6개의 화합물 중 화합물 3 1H NMR 스펙트럼을 나타낸 도면이다.
도 11은 본 발명에 따른 매괴화 추출물에서 분리된 6개의 화합물 중 화합물 5의 1H NMR 스펙트럼을 나타낸 도면이다.
도 12는 본 발명에 따른 매괴화 추출물에서 분리된 6개의 화합물 중 화합물 6의 1H NMR 스펙트럼을 나타낸 도면이다.1 is a view showing the separation process of
Figure 2 is a diagram showing the DPPH activity of the ethyl acetate fraction of the maekkaethwa extract according to the present invention.
Figure 3 is a diagram showing the DPPH activity of the 50% methanol fraction according to the present invention.
Figure 4 shows the DPPH activity for the six compounds isolated from the 50% methanol fraction according to the present invention.
Figure 5 is a view showing the results of UPLC analysis of the six compounds isolated from the extract according to the present invention.
Figure 6 is a view showing the ultraviolet spectrum of the six compounds isolated from the extract according to the present invention.
7 is a view showing the UPLC-HR-ESI-MS spectrum of the six compounds isolated from the extract according to the present invention.
Figure 8 is a diagram showing the 1H NMR spectrum of
Figure 8 is a diagram showing the 1H NMR spectrum of
9 is a view showing the 1H NMR spectrum of
FIG. 10 is a diagram showing a 1H NMR spectrum of
11 is a diagram showing the 1H NMR spectrum of
12 is a diagram showing the 1H NMR spectrum of
본 발명은 매괴화 추출물로부터 분리한 화학식 1 내지 6의 화합물로 이루어진 군으로부터 선택되는 1 종 이상의 화합물을 유효성분으로 함유하는 화장품용 항산화 조성물에 관한 것이다.The present invention relates to an antioxidant composition for cosmetics containing as an active ingredient at least one compound selected from the group consisting of compounds of
[화학식 1][Formula 1]
화학식 1로 표시되는 화합물 1은 Rutin으로 지칭될 수 있다.
MW(분자량) : 610.51 MW (molecular weight): 610.51
Molecular Formula(분자식) : C27H30O16 Molecular Formula: C 27 H 30 O 16
[화학식 2][Formula 2]
화학식 2로 표시되는 화합물 2는 Hyperoside로 지칭될 수 있다.
MW(분자량) : 464.37 MW (molecular weight): 464.37
Molecular Formula(분자식) : C21H20O12 Molecular Formula: C 21 H 20 O 12
[화학식 3][Formula 3]
화학식 3으로 표시되는 화합물 3은 Isoquercitrin으로 지칭될 수 있다.
MW(분자량) : 464.09 MW (molecular weight): 464.09
Molecular Formula(분자식) : C21H20O12 Molecular Formula: C 21 H 20 O 12
[화학식 4][Formula 4]
화학식 4로 표시되는 화합물 4는 Hyperin 6''-gallate로 지칭될 수 있다.
MW(분자량) : 616.48 MW (molecular weight): 616.48
Molecular Formula(분자식) : C28H24O16 Molecular Formula: C 28 H 24 O 16
[화학식 5][Formula 5]
화학식 5로 표시되는 화합물 5는 Avicularin로 지칭될 수 있다.
MW(분자량) : 434.08 MW (molecular weight): 434.08
Molecular Formula(분자식) : C20H18O11 Molecular Formula: C 20 H 18 O 11
[화학식 6][Formula 6]
화학식 6으로 표시되는 화합물 6은 2-Phenylethyl 6-O-galloyl-β-D-glucopyranoside로 지칭될 수 있다.
MW(분자량) : 436.14MW (molecular weight): 436.14
Molecular Formula(분자식) : C21H24O10 Molecular Formula: C 21 H 24 O 10
상기 매괴화 추출물로부터 분리한 화학식 1 내지 6의 화합물은 매괴화 추출물의 에틸아세테이트 분획물로부터 분리한 것이며, 상기 매괴화 추출물로부터 분리한 화합물은 5개의 플라보노이드 화합물과 1개의 페놀 화합물이다.The compounds of
먼저, 상기 매괴화 추출물은 친수성 용매로 추출된 것이며, 상기 친수성 용매는 물, 알코올 또는 이들의 혼합물일 수 있다. 상기 알코올은 에탄올, 메탄올, n-프로판올, 이소프로판올, n-부탄올, sec-부탄올, 이소부탄올, tert-부탄올 또는 이들의 혼합물일 수 있으나 이에 제한되지 않는다. 본 발명에서는 상기 매괴화 추출물의 추출용매로 100% 에탄올을 사용하여 추출한다.First, the lumping extract is extracted with a hydrophilic solvent, and the hydrophilic solvent may be water, alcohol, or a mixture thereof. The alcohol may be ethanol, methanol, n-propanol, isopropanol, n-butanol, sec-butanol, isobutanol, tert-butanol, or a mixture thereof, but is not limited thereto. In the present invention, the extract is extracted using 100% ethanol as an extraction solvent for the lumping extract.
그리고, 매괴화 추출물을 분획 용매를 사용하여 분획물을 제조함에 있어서, 본 발명에서는 에틸아세테이트를 이용하여 분획물을 제조하였다.In addition, in preparing a fraction using a fractionation solvent for the lumped extract, in the present invention, a fraction was prepared using ethyl acetate.
또한, 상기 매괴화 추출물의 에틸아세테이트 분획물로터 분리된 화합물은 크로마토그래피 또는 여과일 수 있으며, 상기 크로마토그래피는 컬럼 크로마토그래피, 고성능액체 크로마토그래피(HPLC), 이온교환 크로마토그래피, 친화성 크로마토그래피 및 크기배제 크로마토그래피 또는 그 조합일 수 있다.In addition, the compound separated from the ethyl acetate fraction of the massif extract may be chromatography or filtration, and the chromatography may be column chromatography, high performance liquid chromatography (HPLC), ion exchange chromatography, affinity chromatography, and size. It may be exclusion chromatography or a combination thereof.
상기 매괴화 추출물의 에틸아세테이트 분획물로부터 분리된 화합물은 항산화 성분을 갖는 화장품의 조성물로 사용될 수 있다.The compound isolated from the ethylacetate fraction of the maegaehwa extract can be used as a cosmetic composition having an antioxidant component.
또한, 전체 조성물에 대하여, 매괴화 추출물의 에틸아세테이트 분획물로부터 분리된 화합물을 0.1~10중량%를 유효성분으로 포함하는 것이 바람직하다.In addition, with respect to the total composition, it is preferable to include 0.1 to 10% by weight of the compound isolated from the ethylacetate fraction of the maebustion extract as an active ingredient.
이는 최소한의 항산화 성분 효과를 달성할 수 있도록 조성물의 함량은 상기 최소치 이상인 것이 바람직하며, 과량 첨가에 따른 사용감 저하 및 각종 제형에의 적용가능성을 고려하여 조성물의 함량은 상기 최대치 이하인 것이 바람직하다.It is preferable that the content of the composition is more than the minimum value so as to achieve the minimum antioxidant effect, and the content of the composition is preferably less than the maximum value in consideration of the reduction in feeling of use and applicability to various formulations due to excessive addition.
이하에서 실시예를 통하여 본 발명을 더욱 구체적으로 설명한다. 그러나 하 기의 실시예는 본 발명을 구체적으로 예시하기 위한 것일 뿐, 본 발명의 권리범위를 제한하는 것이 아님은 통상의 기술자에게 있어서 명백한 사실이다. 즉, 본 발명의 단순한 변형 내지 변경은 통상의 기술자에 의하여 용이하게 실시될 수 있으며, 이러한 변형이나 변경은 모두 본 발명의 영역에 포함되는 것으로 볼 수 있다.Hereinafter, the present invention will be described in more detail through examples. However, the following examples are for illustrative purposes only, and are not intended to limit the scope of the present invention, which is obvious to those skilled in the art. That is, simple modifications or changes of the present invention can be easily implemented by a person skilled in the art, and all such modifications or changes can be considered to be included in the scope of the present invention.
실시예 1 : 매괴화 추출물, 분획물 제조 및 분획물로부터 화합물 분리Example 1: Preparation of the extract, fraction and separation of the compound from the fraction
도 1은 매괴화로부터 분리한 화합물 1 내지 6의 분리과정을 나타낸 도면이다.1 is a diagram showing the separation process of
도 1을 참조하여 매괴화 추출물, 분획물 제조 및 분획물로부터 화합물 분리 방법을 설명하면, 매괴화 1kg을 50℃에서 100% 에탄올 3L로 추출하였다. 상기 추출한 매괴회추출물 70g을 물 2L에 현탁시키고 에틸아세테이트로 분획시켰다. 에틸아세테이트 분획을 감압하에 증발시켜 26g의 갈색 잔류물을 수득하였다. 용매 분획을 DPPH- 소거 활성에 대해 시험하였다. 이 중 에틸아세테이트 분획은 항산화제 활성을 나타냈다.Referring to Figure 1 to describe the method of separating the compound from the fractions and the extract, the fraction and the fractions, 1 kg of the cultivation was extracted with 3L of 100% ethanol at 50°C. 70 g of the extracted barberry ash extract was suspended in 2 L of water and fractionated with ethyl acetate. The ethyl acetate fraction was evaporated under reduced pressure to give 26 g of a brown residue. The solvent fraction was tested for DPPH- scavenging activity. Among them, the ethyl acetate fraction showed antioxidant activity.
상기 분획된 분획물 26g을 메탄올과 물(0:100, 30:70, 50:50, 70:30 및 100:0)을 사용하여 단계 구배 용출로 역상 컬럼 크로마토 그래피(YMC- 겔 RP-C18, 70-230 메쉬, 500g) 각 500mL로 용리시켜 5개의 분획물(Fr.1 내지 5)을 수득하였다. 다시 Fr. 3(12.8g)을 추가로 메탄올-물(단계별로 20:80 내지 100:0 ; 500mL)의 단계적 구배를 사용하여 RP 컬럼 크로마토 그래피로 정제하여 12개의 분획물(Fr.3-1 내지 Fr.3-12)을 HPLC(YMC-Pack ODS-A, 5㎛, φ20 × 150mm, UV 254nm, 유속 2㎖/분)에 의해 3-6(1.1g)을 순차적으로 분리하고, 화합물 1(16.5mg), 화합물 2(21.4mg), 화합물 3(48.1mg), 화합물 4(4mg),화합물 5(6.3mg) 및 화합물 6(40.7mg)을 수득하였다.26 g of the fractionated fraction was subjected to reverse phase column chromatography (YMC-gel RP-C18, 70) by step gradient elution using methanol and water (0:100, 30:70, 50:50, 70:30 and 100:0). -230 mesh, 500g) was eluted with each 500mL to obtain 5 fractions (Fr. 1 to 5). Again Fr. 3 (12.8 g) was further purified by RP column chromatography using a stepwise gradient of methanol-water (step by step 20:80 to 100:0; 500 mL) to obtain 12 fractions (Fr.3-1 to Fr.3). -12) 3-6 (1.1g) was sequentially separated by HPLC (YMC-Pack ODS-A, 5㎛, φ20 × 150mm, UV 254nm, flow rate 2ml/min), and Compound 1 (16.5mg) , Compound 2 (21.4 mg), Compound 3 (48.1 mg), Compound 4 (4 mg), Compound 5 (6.3 mg) and Compound 6 (40.7 mg) were obtained.
도 2는 매괴화 추출물의 에틸아세테이트 분획물과 분획의 DPPH 활성을 나타낸 것이며, 도 3은 50% 메탄올 분획의 DPPH 활성을 나타낸 것이며, 도 4는 50% 메탄올 분획물에서 분리된 6개의 화합물에 대한 DPPH 활성을 나타낸 것이다.Figure 2 shows the DPPH activity of the ethyl acetate fraction and the fraction of the maehwa extract, Figure 3 shows the DPPH activity of the 50% methanol fraction, Figure 4 is the DPPH activity for the six compounds isolated from the 50% methanol fraction Is shown.
실험예 1 : 매괴화 추출물에서 분리된 6개의 화합물 분석Experimental Example 1: Analysis of 6 compounds isolated from the extract of maebustion
(1) UPLC/MS 분석(1) UPLC/MS analysis
매괴화 추출물에서 분리된 6개의 화합물을 UPLC/Q-TOF MS로 분석하였다.The six compounds isolated from the maehwa extract were analyzed by UPLC/Q-TOF MS.
UPLC/MS 분석은 Waters SYNAPT G2-Si 고화질 질량 분광기와 결합된 Waters ACQUITY UPLC시스템에서 수행되었다. 크로마토그래피 분리는 35℃에서 ACQUITY UPLC HSS C18(100mm × 2.1mm, 1.8μm) 컬럼을 사용하고, 10℃의 자동 샘플러 온도에서 수행하였다. 이동상 A는 물로 구성되고, 이동상 B는 아세토니트릴로 구성된다. 용매는 초기에 20% B로부터 0.3mL/min의 유속에서 50분에 걸쳐 20~30% B로 변화한다(표 1). 이어서 다음 샘플 주입 전에 95% B를 사용하여 15분 동안 세척하였다. UV 검출기를 사용하여 254nm에서 크로마토 그램을 모니터링했다.UPLC/MS analysis was performed on a Waters ACQUITY UPLC system combined with a Waters SYNAPT G2-Si high-definition mass spectrometer. Chromatographic separation was performed at 35° C. using an ACQUITY UPLC HSS C18 (100 mm×2.1 mm, 1.8 μm) column, and at 10° C. auto sampler temperature. Mobile phase A consists of water and mobile phase B consists of acetonitrile. The solvent initially changes from 20% B to 20-30% B over 50 minutes at a flow rate of 0.3 mL/min (Table 1). It was then washed for 15 minutes with 95% B before the next sample injection. The chromatogram was monitored at 254 nm using a UV detector.
UPLC-HR-MS 분석을 위해, 음이온 전기 분무 모드에서 모세관 전압 및 원추 전압을 2.0kV로 설정하였다.For UPLC-HR-MS analysis, capillary voltage and cone voltage were set to 2.0 kV in negative ion electrospray mode.
질량 분석은 20nL/min의 유속에서 leukine enkephalin (Sigma Aldrich) 300 ng/mL 용액으로 구성된 외부 기준(Lock-Spray)을 사용하여 획득 중에 보정하였고, 정확성과 재현성을 보장하기 위해 음이온 모드([M-H] - m / z = 554.2615)로 기준 이온을 생성하였다. 그 결과는 도 5에 나타내었다.Mass spectrometry was calibrated during acquisition using an external reference (Lock-Spray) consisting of 300 ng/mL solution of leukine enkephalin (Sigma Aldrich) at a flow rate of 20 nL/min, and negative ion mode ([MH]) to ensure accuracy and reproducibility. -m / z = 554.2615) to generate a reference ion. The results are shown in FIG. 5.
(2) HPLC-PDA 분석(2) HPLC-PDA analysis
HPLC 분석은 Shimadzu-HPLC 시스템 (Shimadzu Corporation, Kyoto, Japan)에서 수행되었으며, CBM-20A 제어기, LC-20AP 펌프 및 SPD-M20A 포토 다이오드 어레이(PDA) 검출기가 포함된다. 크로마토그래피 분리는 Luna C18 역상 컬럼(250㎜ × 4.6㎜, 5㎛)상에서 달성되었다. 분석 조건은 아래 표 2와 같다.HPLC analysis was performed on a Shimadzu-HPLC system (Shimadzu Corporation, Kyoto, Japan) and included a CBM-20A controller, LC-20AP pump and SPD-M20A photodiode array (PDA) detector. Chromatographic separation was achieved on a Luna C18 reverse phase column (250 mm x 4.6 mm, 5 μm). Analysis conditions are shown in Table 2 below.
(3) DPPH 라디칼 소거능 측정(3) DPPH radical scavenging ability measurement
DPPH(1,1-diphenyl-2-picrylhydrazyl) 분석은 항산화활성 측정 방법 중 가장 널리 이용되는 방법이며, 모든 실험은 3번 수행되었다. Ascorbic acid를 양성 대조군으로 사용하였고, 항산화 활성 프로파일은 DPPH (1,1-diphenyl-2picrylhydrazyl)를 사용하여 각 분획의 라디칼 소거능을 측정함으로써 생성되었다. 각 분획을 진공 농축기를 사용하여 원심 분리기로 건조시키고 메탄올에서 재구성하여 10mg/mL 저장 용액을 만들었다. 22 개의 모든 원액을 메탄올로 희석하고 150μM DPPH 수용액 190μL와 혼합하였다.DPPH (1,1-diphenyl-2-picrylhydrazyl) analysis is the most widely used method of measuring antioxidant activity, and all experiments were performed three times. Ascorbic acid was used as a positive control, and the antioxidant activity profile was generated by measuring the radical scavenging ability of each fraction using DPPH (1,1-diphenyl-2picrylhydrazyl). Each fraction was dried with a centrifuge using a vacuum concentrator and reconstituted in methanol to make a 10 mg/mL stock solution. All 22 stock solutions were diluted with methanol and mixed with 190 μL of 150 μM DPPH aqueous solution.
나머지 DPPH의 흡광도는 20 분후 517 nm에서 다음과 같이 측정되었다.The absorbance of the remaining DPPH was measured at 517 nm after 20 minutes as follows.
Abt = 시험된 추출물을 사용한 DPPH 용액의 흡광도Ab t = absorbance of DPPH solution using the tested extract
Ab0 = 에탄올 첨가시 DPPH 용액의 흡광도Ab 0 = absorbance of DPPH solution upon addition of ethanol
Abb = 메탄올을 첨가하여 시험한 추출 용액의 흡광도.Ab b = absorbance of the extraction solution tested by adding methanol.
(4) 결과(4) result
UV 스펙트럼을 각 화합물 6개와 본 발명의 매괴화 추출물에서 분리된 6개의 화합물과 비교하여 6가지 화합물은 5개의 플라보노이드 화합물과 하나의 페놀 화합물로 확인했다. 화합물의 구조는 HR-ESI-MS, NMR 및 문헌에서의 NMR 분석에 의해 확립되었다. 그 결과는 도 6에 나타내었다.The UV spectra were compared with each of the 6 compounds and the 6 compounds isolated from the cultivated extract of the present invention, and the 6 compounds were identified as 5 flavonoid compounds and one phenolic compound. The structure of the compound was established by HR-ESI-MS, NMR and NMR analysis in the literature. The results are shown in FIG. 6.
또한, 본 발명의 매괴화 추출물에서 분리된 6개의 화합물은 NMR 분석에 의해 그 구조는 화학적 증거, 물리적 방법 및 문헌에서 보고된 구조와 비교하여 결정되었다. 그 결과는 도 7 및 아래 표 3, 4에 나타내었다.In addition, the structure of the six compounds isolated from the extract of the present invention was determined by NMR analysis by comparison with chemical evidence, physical methods, and structures reported in the literature. The results are shown in Fig. 7 and Tables 3 and 4 below.
표 4를 통하여 알 수 있는 바와 같이, 화합물 1 내지 6을 비교하면, (6) > (5) > (3) > (1) > (2) > (4) 순으로, 이들 화합물에 대한 자유라디컬 실험을 통한 항산화능을 확인할 수 있다. 분리정제된 6개의 화합물 중에서, 화합물 6은 항산화 효과가 제일 높게 나타났다.As can be seen from Table 4, when comparing
Claims (5)
매괴화 1kg을 50℃에서 100% 에탄올 3L로 추출하고, 상기 추출한 매괴화추출물 70g을 물 2L에 현탁시키고 에틸아세테이트로 분획시킨 후, 상기 에틸아세테이트 분획물에 메탄올과 물을 중량대비 0:100, 30:70, 50:50, 70:30 및 100:0을 사용하여 역상 컬럼 크로마토그래피에 용리시켜 5개의 분획물을 수득한 후, 상기 분획물 중 메탄올과 물을 중량대비 50:50으로 분획한 분획물을 메탄올-물의 단계적 구배를 사용하여 역상 컬럼 크로마토그래피로 정제시켜 12개의 분획물을 수득하고, 다시 고성능액체 크로마토그래피를 통해 분리한 화학식 1 내지 6으로 이루어진 화합물을 유효성분으로 함유하되,
상기 매괴화 추출물의 에틸아세테이트 분획물로부터 분리된 화합물 0.1~10중량%를 유효성분으로 포함하는 것을 특징으로 하는 화장품용 항산화 조성물.
[화학식 1]
[화학식 2]
[화학식 3]
[화학식 4]
[화학식 5]
[화학식 6]
In the cosmetic composition having an antioxidant component,
1 kg of crushed mass was extracted with 3L of 100% ethanol at 50°C, and 70 g of the extracted mass lumped extract was suspended in 2L of water and fractionated with ethyl acetate, and methanol and water were added to the ethyl acetate fraction by weight of 0:100, 30 :70, 50:50, 70:30, and 100:0 were eluted by reverse-phase column chromatography to obtain 5 fractions, and the fraction obtained by dividing methanol and water at a weight ratio of 50:50 among the fractions was methanol. -Twelve fractions were obtained by purification by reverse phase column chromatography using a stepwise gradient of water, and a compound consisting of Formulas 1 to 6 separated through high performance liquid chromatography was contained as an active ingredient,
Cosmetic antioxidant composition comprising 0.1 to 10% by weight of the compound isolated from the ethyl acetate fraction of the maebustion extract as an active ingredient.
[Formula 1]
[Formula 2]
[Formula 3]
[Formula 4]
[Formula 5]
[Formula 6]
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180172779A KR102240357B1 (en) | 2018-12-28 | 2018-12-28 | Antioxidant composition for cosmetics containing a compound isolated from extract of Rosa rugosa Thumb |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180172779A KR102240357B1 (en) | 2018-12-28 | 2018-12-28 | Antioxidant composition for cosmetics containing a compound isolated from extract of Rosa rugosa Thumb |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20200082315A KR20200082315A (en) | 2020-07-08 |
KR102240357B1 true KR102240357B1 (en) | 2021-04-14 |
Family
ID=71600351
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020180172779A KR102240357B1 (en) | 2018-12-28 | 2018-12-28 | Antioxidant composition for cosmetics containing a compound isolated from extract of Rosa rugosa Thumb |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102240357B1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102617783B1 (en) * | 2021-02-17 | 2023-12-22 | 원광대학교산학협력단 | Cosmetic composition for suppressing aging comprising Rosa rugosa flower extract and rosamultin |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100262296B1 (en) * | 1997-10-25 | 2000-08-01 | 박호군 | Use of β-glucogallin as anti-oxidation agent and isolation process of β-glucogallin |
KR20130065185A (en) | 2011-12-09 | 2013-06-19 | 대구한의대학교산학협력단 | A natural food additive comprising an extract of rosa rugosa as an active ingredient, and the preparation thereof |
EP3326638A4 (en) | 2015-07-17 | 2019-01-09 | Korea Research Institute of Bioscience and Biotechnology | Pharmaceutical composition for preventing or treating il-6-mediated diseases comprisingrosa rugosa |
-
2018
- 2018-12-28 KR KR1020180172779A patent/KR102240357B1/en active IP Right Grant
Non-Patent Citations (3)
Title |
---|
Determination of the volatile and polyphenol constituents and the antimicrobial, antioxidant, and tyrosinase inhibitory activities of the bioactive compounds from the by-product of Rosa rugosa Thunb. var. plena Regal tea, BMC Complementary Medicine and Therapies,18, 307(2018.11.20.) 1부.* |
Evaluation of rose roots, a post-harvest plantation residue as a source of phytochemicals with radical scavenging, cytotoxic, and antimicrobial activity, Industrial Crops and Products, 69, 129-136(2015.02.20.) 1부.* |
South African Journal of Botany, 91, pp.37-42(2013.12.22.) |
Also Published As
Publication number | Publication date |
---|---|
KR20200082315A (en) | 2020-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Dai et al. | Preparative isolation and purification of seven main antioxidants from Eucommia ulmoides Oliv.(Du-zhong) leaves using HSCCC guided by DPPH-HPLC experiment | |
Oniszczuk et al. | Extraction methods for the determination of phenolic compounds from Equisetum arvense L. herb | |
Gouveia et al. | Artemisia annua L.: Essential oil and acetone extract composition and antioxidant capacity | |
Maietti et al. | Metabolite profiling of flavonols and in vitro antioxidant activity of young shoots of wild Humulus lupulus L.(hop) | |
Mahfoudhi et al. | Metabolite profiling of polyphenols in the Tunisian plant Tamarix aphylla (L.) Karst. | |
Juan-Badaturuge et al. | Antioxidant principles of Tanacetum vulgare L. aerial parts | |
Maldini et al. | Phenolic compounds from Byrsonima crassifolia L. bark: Phytochemical investigation and quantitative analysis by LC-ESI MS/MS | |
Song et al. | Determination of polyphenol components of Korean prostrate spurge (Euphorbia supina) by using liquid chromatography—tandem mass spectrometry: overall contribution to antioxidant activity | |
Niu et al. | Main iridoid glycosides and HPLC/DAD-Q-TOF-MS/MS profile of glycosides from the antioxidant extract of Eucommia ulmoides Oliver seeds | |
Bhandari et al. | Online HPLC-DPPH method for antioxidant activity of Picrorhiza kurroa Royle ex Benth. and characterization of kutkoside by Ultra-Performance LC-electrospray ionization quadrupole time-of-flight mass spectrometry | |
Veryser et al. | N-alkylamide profiling of Achillea ptarmica and Achillea millefolium extracts by liquid and gas chromatography–mass spectrometry | |
Vijayalakshmi et al. | Phytochemical screening by LC-MS analysis and invitro anti-inflammatory activity of Marselia quadrifolia plant extract | |
KR102240357B1 (en) | Antioxidant composition for cosmetics containing a compound isolated from extract of Rosa rugosa Thumb | |
CN103130851B (en) | A kind of method being separated preparation four kinds of pelargonin derivatives from radish skin | |
US8282968B2 (en) | Bioactive water fraction from Gomphostemma niveum | |
Šavikin et al. | Crataegus orientalis leaves and berries: Phenolic profiles, antioxidant and anti-inflammatory activity | |
Cao et al. | Occurrence and biological activities of phenylpropionyl iridoids | |
Quan et al. | Xanthone constituents of the fruits of Garcinia mangostana with anticomplement activity | |
KR20110048401A (en) | Method for preparing the extract fortified with chalcones from by-product of Angelica keiskei juice | |
Fecka et al. | TLC determination of tannins and flavonoids in extracts from some Erodium species using chemically modified stationary phases | |
Destandau et al. | Centrifugal partition chromatography directly interfaced with mass spectrometry for the fast screening and fractionation of major xanthones in Garcina mangostana | |
Luo et al. | Anti-inflammatory activity of the extracts and fractions from Erigeron multiradiatus through bioassay-guided procedures | |
Tirloni et al. | Influence of Luehea divaricata Mart. extracts on peripheral vascular resistance and the role of nitric oxide and both Ca+ 2-sensitive and Kir6. 1 ATP-sensitive K+ channels in the vasodilatory effects of isovitexin on isolated perfused mesenteric beds | |
KR102176710B1 (en) | A cosmetic composition comprising fractions of extracts of flower of Forsythia koreana as an active ingredient | |
Koca et al. | Evaluation of in vivo and in vitro biological activities of different extracts of Cuscuta arvensis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
X701 | Decision to grant (after re-examination) | ||
GRNT | Written decision to grant |